CardioVia

CardioVia

General
Jobs 0
Shortlists/Awards 1
Pricing strategy 0
Partners/Competitors 0
Last update: Dec 6, 2024 Last update: Dec 6, 2024
General
Jobs
Shortlists/Awards
Pricing strategy
Partners/Competitors

Details

Legal residence:Israel
Organization type:Consulting organization
Funding agencies:Other, Horizon 2020
Other, Horizon 2020 (2014 - 2020)
Sectors:Health, Laboratory & Measurement
Health, Laboratory & Measurement
Sanctions:Check now
Status:
Active

Attachments 0

About

We at CardioVia are developing minimal invasive access to the outer surface of the heart via the pericardium which is a double-walled sac that surrounds the heart.

The outer surface of the heart has been recognized as a promising entry route for the treatment of the most prevalent cardiovascular diseases such as cardiac tamponade, mapping & ablation for various arrhythmias such as Atrial fibrillation and Ventricular tachycardia, left atrial appendage closure, epicardial lead placement and in the future, epicardial pacemaker implantation, drug, stem cells and gene therapy.

These devices and opportunities will unfold greatly once safely and reliably epicardial access will be achieved. It is estimated that, annually, 2.5M patients in the US and the EU will benefit from epicardial access due to a variety of pathological conditions.

By using cutting edge technologies with the simplest ideas, CardioVia will be able to provide physicians with the right access to perform advanced cardiac treatments on the outer surface of the heart like never seen before. By using CardioVia's device, physicians will be able to perform procedures on one of the most delicate and complicated instruments that the human body has.

Awards

Top partners

Top competitors

Want to unlock full information?
Register with us or sign in to access the organization database.
Similar Companies